| David W Dugan, DO | |
|
203 Nw R. D. Mize Rd, Suite # 250, Blue Springs, MO 64014-2513 | |
| (816) 220-5123 | |
| (816) 220-3085 |
| Full Name | David W Dugan |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 15 Years |
| Location | 203 Nw R. D. Mize Rd, Blue Springs, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437464047 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 2010025561 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Kansas City Hospital Home Health Services | North kansas city, MO | Home health agency |
| Cameron Regional Medical Center | Cameron, MO | Hospital |
| North Kansas City Hospital | North kansas city, MO | Hospital |
| Harrison County Community Hospital | Bethany, MO | Hospital |
| Overland Park Reg Med Ctr | Overland park, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopedic Surgeons Pa | 8527034123 | 29 |
| Orthopedic Surgeons Pa | 8527034123 | 29 |
| Performance Plus Rehabilitation Center Llc | 5294791695 | 84 |
| Select Physical Therapy Holdings Inc | 9537076401 | 1487 |
News Archive
Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).
In a study published in the journal Dementia and Geriatric Cognitive Disorder, researchers reported on their effort to improve and validate tools used to assess the severity of a condition called delirium, an acute confusional state often experienced by older hospitalized patients.
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.
The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.
A study by researchers in Scotland confirms that for most women who take the contraceptive pill, the benefits far outweigh any potential risks.
› Verified 8 days ago
| Entity Name | Orthopedic Surgeons Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841264835 PECOS PAC ID: 8527034123 Enrollment ID: O20040904000009 |
News Archive
Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).
In a study published in the journal Dementia and Geriatric Cognitive Disorder, researchers reported on their effort to improve and validate tools used to assess the severity of a condition called delirium, an acute confusional state often experienced by older hospitalized patients.
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.
The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.
A study by researchers in Scotland confirms that for most women who take the contraceptive pill, the benefits far outweigh any potential risks.
› Verified 8 days ago
| Entity Name | Harrison County Community Hospital District |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1528062569 PECOS PAC ID: 4587630926 Enrollment ID: O20071201000173 |
News Archive
Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).
In a study published in the journal Dementia and Geriatric Cognitive Disorder, researchers reported on their effort to improve and validate tools used to assess the severity of a condition called delirium, an acute confusional state often experienced by older hospitalized patients.
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.
The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.
A study by researchers in Scotland confirms that for most women who take the contraceptive pill, the benefits far outweigh any potential risks.
› Verified 8 days ago
| Entity Name | Liberty Hospital Urgent Care, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558778373 PECOS PAC ID: 3375866163 Enrollment ID: O20141231001624 |
News Archive
Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).
In a study published in the journal Dementia and Geriatric Cognitive Disorder, researchers reported on their effort to improve and validate tools used to assess the severity of a condition called delirium, an acute confusional state often experienced by older hospitalized patients.
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.
The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.
A study by researchers in Scotland confirms that for most women who take the contraceptive pill, the benefits far outweigh any potential risks.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David W Dugan, DO 2790 Clay Edwards Dr Ste 650, Kansas City, MO 64116-3279 Ph: (816) 459-7500 | David W Dugan, DO 203 Nw R. D. Mize Rd, Suite # 250, Blue Springs, MO 64014-2513 Ph: (816) 220-5123 |
News Archive
Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).
In a study published in the journal Dementia and Geriatric Cognitive Disorder, researchers reported on their effort to improve and validate tools used to assess the severity of a condition called delirium, an acute confusional state often experienced by older hospitalized patients.
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.
The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.
A study by researchers in Scotland confirms that for most women who take the contraceptive pill, the benefits far outweigh any potential risks.
› Verified 8 days ago
Dr. Angela K Walker, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Nw R D Mize Rd, Blue Springs, MO 64014 Phone: 816-655-5426 Fax: 816-655-5408 | |
Dr. Derec Stanislav, DO Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 201 Nw Rd Mize Road, Blue Springs, MO 64014 Phone: 816-655-5426 Fax: 816-655-5408 | |
Dr. Elijah G Miller, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Nw Rd Mize Road, Blue Springs, MO 64014 Phone: 816-655-5426 Fax: 816-655-5408 | |
Kevin Andrew Witte, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 203 Nw R.d. Mize Rd, Ste 250, Blue Springs, MO 64014 Phone: 816-220-8727 Fax: 816-220-8269 | |
Michael Jason Justice, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 203 Nw Rd Mize Road, Suite #250, Blue Springs, MO 64014 Phone: 816-220-8727 Fax: 816-220-8269 | |
Dr. Katherine Paul, DO Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 201 Nw Rd Mize Road, Blue Springs, MO 64014 Phone: 816-220-8727 Fax: 816-220-8269 |